Abstract is: Hanneke Schuitemaker is a Dutch virologist, the Global Head of Viral Vaccine Discovery and Translational Medicine at Johnson & Johnson's Janssen Vaccines & Prevention, and a Professor of Virology at the Amsterdam University Medical Center of the University of Amsterdam (since 2004). She has been involved in the development of Janssen's Ebola vaccine and is involved in the development of a universal flu vaccine, HIV vaccine, RSV vaccine and COVID-19 vaccine.
| human | Q5 |
| P2671 | Google Knowledge Graph ID | /g/113v9t3jz |
| P213 | ISNI | 0000000390325695 |
| P244 | Library of Congress authority ID | n00119850 |
| P8189 | National Library of Israel J9U ID | 987007364740905171 |
| P214 | VIAF ID | 283934140 |
| 3720161212206340070001 |
| P166 | award received | Inspiring Fifty | Q108466355 |
| P1477 | birth name | Johanna Schuitemaker | |
| P27 | country of citizenship | Kingdom of the Netherlands | Q29999 |
| P69 | educated at | University of Amsterdam | Q214341 |
| P108 | employer | University of Amsterdam | Q214341 |
| Johnson & Johnson | Q333718 | ||
| Sanquin | Q1988022 | ||
| Academic Medical Center | Q2487297 | ||
| P734 | family name | Schuitemaker | Q106859175 |
| Schuitemaker | Q106859175 | ||
| Schuitemaker | Q106859175 | ||
| P735 | given name | Johanna | Q4120836 |
| Johanna | Q4120836 | ||
| Hanneke | Q21056424 | ||
| Hanneke | Q21056424 | ||
| P106 | occupation | researcher | Q1650915 |
| virologist | Q15634281 | ||
| P5008 | on focus list of Wikimedia project | gender gap on Dutch Wikipedia | Q60687720 |
| WikiProject COVID-19 | Q87748614 | ||
| P21 | sex or gender | female | Q6581072 |
| Q94127087 | 2775. Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years |
| Q94122459 | 902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults |
| Q54237723 | A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers. |
| Q54229945 | A comparative study between outbred and inbred rat strains for the use in in vivo IPV potency testing. |
| Q34492100 | A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism |
| Q80714316 | A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef |
| Q85389317 | A sweet surprise for HIV broadly neutralizing antibodies |
| Q43717301 | Absence of HIV-1 superinfection 1 year after infection between 1985 and 1997 coincides with a reduction in sexual risk behavior in the seroincident Amsterdam cohort of homosexual men. |
| Q35077704 | Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic |
| Q98945209 | Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters |
| Q98708535 | Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses |
| Q37486401 | Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys |
| Q28485505 | Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species |
| Q58038022 | Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level |
| Q40080155 | Adenoviral type 35 and 26 vectors with a bidirectional expression cassette in the E1 region show an improved genetic stability profile and potent transgene-specific immune response |
| Q56337689 | Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge |
| Q59358525 | Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses |
| Q37728775 | An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability |
| Q57481193 | An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model |
| Q36330007 | Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform |
| Q35959717 | Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination |
| Q54559313 | Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells. |
| Q43754437 | Association between an interleukin-4 promoter polymorphism and the acquisition of CXCR4 using HIV-1 variants |
| Q82808222 | Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection |
| Q34916745 | Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls |
| Q36845710 | Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection |
| Q34333195 | Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs |
| Q39598885 | CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients |
| Q33959186 | CD39/adenosine pathway is involved in AIDS progression |
| Q56935562 | CTL escape and increased viremia irrespective of HIV-specific CD4+ T-helper responses in two HIV-infected individuals |
| Q81891585 | Causal pathways of the effects of age and the CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on AIDS development |
| Q38962984 | Cell turnover and cell tropism in HIV-1 infection. |
| Q44176443 | Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection |
| Q38412149 | Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study |
| Q39597558 | Comparison of in vivo and in vitro evolution of CCR5 to CXCR4 coreceptor use of primary human immunodeficiency virus type 1 variants |
| Q37692880 | Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer |
| Q89803119 | Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22) |
| Q27674878 | Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies |
| Q36892885 | Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons |
| Q42744666 | Correction: Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination |
| Q47420834 | Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour |
| Q37807442 | Correlations between HIV-1 clades and HIV-1 antibody neutralization sensitivity: significant for vaccine development? |
| Q56886558 | Cross‐Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression |
| Q45721887 | Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection |
| Q47806708 | Depletion of naive CD4 T cells by CXCR4-using HIV-1 variants occurs mainly through increased T-cell death and activation |
| Q33951977 | Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing |
| Q40390133 | Determination of cell tropism of HIV-1. |
| Q40390125 | Determination of co-receptor usage of HIV-1. |
| Q40306609 | Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease |
| Q42196133 | Differential characteristics of cytotoxic T lymphocytes restricted by the protective HLA alleles B*27 and B*57 in HIV-1 infection |
| Q33851717 | Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology |
| Q84079241 | Donor variation in in vitro HIV-1 susceptibility of monocyte-derived macrophages |
| Q107565125 | Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination |
| Q52007944 | Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection |
| Q51849062 | Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers. |
| Q45722973 | Early viral load and CD4+ T cell count, but not percentage of CCR5+ or CXCR4+ CD4+ T cells, are associated with R5-to-X4 HIV type 1 virus evolution |
| Q46422130 | Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection |
| Q44679186 | Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure |
| Q44775993 | Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity. |
| Q45406304 | Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro. |
| Q56911184 | Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) |
| Q54440186 | Evaluation of pre-screening methods for the identification of HIV-1 superinfection. |
| Q40630382 | Evolution of R5 and X4 human immunodeficiency virus type 1 gag sequences in vivo: evidence for recombination |
| Q35140461 | Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum |
| Q52580309 | First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. |
| Q42990415 | GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study |
| Q45353994 | Gag sequence variation in a human immunodeficiency virus type 1 transmission cluster influences viral replication fitness |
| Q38415610 | Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection |
| Q33979751 | Genome-wide association scan in HIV-1-infected individuals identifying variants influencing disease course. |
| Q38037603 | Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics |
| Q21135536 | Genome-wide association study identifies single nucleotide polymorphism in DYRK1A associated with replication of HIV-1 in monocyte-derived macrophages |
| Q28943289 | Genome-wide association study implicates PARD3B-based AIDS restriction |
| Q34571277 | Genome-wide association study on the development of cross-reactive neutralizing antibodies in HIV-1 infected individuals |
| Q74221349 | HIV tropism and CD4+ T-cell depletion |
| Q58375783 | HIV-1 Subtype C Gag-Specific T-Cell Responses in Relation to Human Leukocyte Antigens in a Diverse Population of HIV-Infected Ethiopians |
| Q45765336 | HIV-1 envelope characteristics that coincide with the development of cross-reactive neutralizing activity in HIV-1 infected patients. |
| Q84066774 | HIV-1 envelope diversity 1 year after seroconversion predicts subsequent disease progression |
| Q34990575 | HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans |
| Q37360774 | HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. |
| Q37073506 | HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds |
| Q42259833 | HIV-1 isolation from infected peripheral blood mononuclear cells. |
| Q35067451 | HIV-1 replication fitness of HLA-B*57/58:01 CTL escape variants is restored by the accumulation of compensatory mutations in gag |
| Q44967514 | HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil |
| Q39489056 | HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy |
| Q33920519 | High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutraliz |
| Q39428882 | Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. |
| Q35156320 | Host genetic factors in the clinical course of HIV-1 infection: chemokines and chemokine receptors |
| Q35773031 | Identification of Genes Whose Expression Profile Is Associated with Non-Progression towards AIDS Using eQTLs |
| Q37059821 | Identification of Sequential Viral Escape Mutants Associated with Altered T-Cell Responses in a Human Immunodeficiency Virus Type 1-Infected Individual |
| Q35077438 | Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques. |
| Q45358427 | Immunization with recombinant macaque major histocompatibility complex class I and II and human immunodeficiency virus gp140 inhibits simian-human immunodeficiency virus infection in macaques. |
| Q28271300 | Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes |
| Q83352082 | Impact of CCR5 Delta32/+ deletion on herpes zoster among HIV-1-infected homosexual men |
| Q34823713 | Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models |
| Q37667749 | Impact of host cell variation on the neutralization of HIV-1 in vitro |
| Q40584611 | In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists |
| Q35743897 | Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies |
| Q45723835 | Increased In Vitro Cytopathicity of CC Chemokine Receptor 5–Restricted Human Immunodeficiency Virus Type 1 Primary Isolates Correlates with a Progressive Clinical Course of Infection |
| Q35634988 | Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. |
| Q40883803 | Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker |
| Q107214410 | Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine |
| Q33410826 | International network for comparison of HIV neutralization assays: the NeutNet report |
| Q28730045 | International network for comparison of HIV neutralization assays: the NeutNet report II |
| Q45397936 | Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals |
| Q80829934 | Isolation and propagation of HIV-1 on peripheral blood mononuclear cells |
| Q45428916 | Isolation, propagation, and titration of human immunodeficiency virus type 1 from peripheral blood of infected individuals |
| Q45728690 | Lack of evidence for an association between a polymorphism in CX3CR1 and the clinical course of HIV infection or virus phenotype evolution |
| Q35077797 | Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies |
| Q35826458 | Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity |
| Q38438218 | Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted by protective HLA-B alleles during the HIV-1 epidemic |
| Q35947741 | Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease |
| Q84142057 | Low incidence of HIV-1 superinfection even after episodes of unsafe sexual behavior of homosexual men in the Amsterdam Cohort Studies on HIV Infection and AIDS |
| Q37738467 | Low level of HIV-1 evolution after transmission from mother to child |
| Q42732104 | Low levels of human immunodeficiency virus type 1 DNA in high-risk seronegative men |
| Q81375635 | Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection |
| Q64968778 | Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users. |
| Q55518397 | Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge. |
| Q33344499 | Molecular evolution of human immunodeficiency virus type 1 upon transmission between human leukocyte antigen disparate donor-recipient pairs |
| Q35808621 | Multicohort genomewide association study reveals a new signal of protection against HIV-1 acquisition |
| Q36696711 | Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-term nonprogression to AIDS. |
| Q45440751 | Natural controlled HIV infection: preserved HIV-specific immunity despite undetectable replication competent virus |
| Q77975790 | Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia |
| Q100394698 | Neutralizing antibody responses induced by HIV-1 envelope glycoprotein SOSIP trimers derived from elite neutralizers |
| Q34220902 | No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial |
| Q31039719 | Novel strategy for the selection of human recombinant Fab fragments to membrane proteins from a phage-display library |
| Q39250141 | PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine |
| Q52012817 | Persistence of viral HLA-DR- CD4 T-cell reservoir during prolonged treatment of HIV-1 infection with a five-drug regimen. |
| Q93150718 | Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine with an Adenovirus 26 Vector Encoding Pre-Fusion F (Ad26.RSV.preF) in adults 60 years and older |
| Q36510410 | Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals |
| Q46036261 | Polymorphism in HIV-1 dependency factor PDE8A affects gene expression and HIV-1 replication in primary macrophages. |
| Q34216644 | Polymorphism in HIV-1 dependency factor PDE8A affects mRNA level and HIV-1 replication in primary macrophages. |
| Q36331886 | Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load |
| Q38484602 | Prediction of residual time to AIDS and death based on markers and cofactors |
| Q45948731 | Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. |
| Q104747757 | Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study |
| Q40646999 | Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies |
| Q37355237 | Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys |
| Q36300153 | Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys |
| Q30448634 | R5 human immunodeficiency virus type 1 infection of fetal thymic organ culture induces cytokine and CCR5 expression |
| Q33725673 | Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors |
| Q41026321 | Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats |
| Q29394572 | Reconstructing the Dynamics of HIV Evolution within Hosts from Serial Deep Sequence Data |
| Q34014318 | Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection |
| Q38437403 | Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 control |
| Q106610416 | Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 |
| Q34522696 | Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial |
| Q98772565 | Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults |
| Q90814672 | Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption |
| Q100429973 | Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study |
| Q36068205 | Screening low-frequency SNPS from genome-wide association study reveals a new risk allele for progression to AIDS |
| Q34984724 | Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model |
| Q46869509 | Short communication: No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients |
| Q59360638 | Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys |
| Q34162648 | Single nucleotide polymorphism in gene encoding transcription factor Prep1 is associated with HIV-1-associated dementia |
| Q98172334 | Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques |
| Q35947805 | Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies |
| Q38835985 | Synthetic virus seeds for improved vaccine safety: Genetic reconstruction of poliovirus seeds for a PER.C6 cell based inactivated poliovirus vaccine |
| Q40217897 | T cell line passage can select for pre-existing neutralization-sensitive variants from the quasispecies of primary human immunodeficiency virus type-1 isolates |
| Q40779309 | The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype |
| Q36155396 | The development of CD4 binding site antibodies during HIV-1 infection |
| Q33318083 | The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection |
| Q45361986 | The evolution of human immunodeficiency virus type-1 (HIV-1) envelope molecular properties and coreceptor use at all stages of infection in an HIV-1 donor-recipient pair |
| Q29417018 | The major genetic determinants of HIV-1 control affect HLA class I peptide presentation |
| Q35009308 | The presence of CXCR4-using HIV-1 prior to start of antiretroviral therapy is an independent predictor of delayed viral suppression |
| Q81332811 | The presence of the Trim5alpha escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase |
| Q27305204 | The role of innate APOBEC3G and adaptive AID immune responses in HLA-HIV/SIV immunized SHIV infected macaques |
| Q33877210 | Time-measured phylogenies of gag, pol and env sequence data reveal the direction and time interval of HIV-1 transmission |
| Q35729899 | Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys |
| Q80819695 | Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection |